Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Portfolio News / By Karina Tin February 14, 2023 Neurona Therapeutics Announces FDA Clearance of Expanded Inclusion Criteria for Phase I/II Clinical Trial of NRTX-1001 Regenerative Cell Therapy in Patients with Dominant Hemisphere Drug-Resistant Focal Epilepsy Read More »
Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules Portfolio News / By Karina Tin February 13, 2023 Hexagon Bio Raises $77.3 Million Series B Financing and Strengthens Leadership to Expand Novel Computational Discovery Platform and Advance Microbial Genome-Derived Small Molecules Read More »
Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Portfolio News / By Karina Tin February 9, 2023 Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Provides a Corporate Update Read More »
ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Portfolio News / By Karina Tin February 3, 2023 ORIC Pharmaceuticals Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) Read More »
Casma Therapeutics Announces CEO Transition Portfolio News / By Karina Tin January 31, 2023 Casma Therapeutics Announces CEO Transition Read More »
Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer Portfolio News / By Karina Tin January 30, 2023 Ribon Therapeutics Announces $25 Million Equity Investment from Pfizer Read More »
Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders Portfolio News / By Karina Tin January 30, 2023 Escient Pharmaceuticals Announces IND Clearance by FDA To Start Phase 1 Study of EP262, A First-in-Class Oral MRGPRX2 Antagonist For Mast Cell Mediated Disorders Read More »
Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics Portfolio News / By Karina Tin January 10, 2023 Atavistik Bio Announces Collaboration with Plex Research to Enrich the Informatics Capabilities of its AMPS Platform and Accelerate the Discovery of Novel Small Molecule Therapeutics Read More »
ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Portfolio News / By Karina Tin January 9, 2023 ORIC Pharmaceuticals Provides Corporate Update and Highlights Key Upcoming Milestones Read More »
NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Portfolio News / By Karina Tin January 9, 2023 NGM Bio Outlines Corporate Strategy and Provides Guidance on Key Priorities Read More »
